Conversely, for head and neck (13.8%, n = 4/29), ovarian (16.7%, n = 3/18), breast (21.8%, n = 12/55), pancreatic (23.4%, n = 11/47) and liver and biliary tract (26.7%, n = 8/30) cancers, TF was less frequently evaluable. This evidence concerns the gene TF and cancer.